Publications
Publications
Show Results For
- All HBS Web
(114)
- Faculty Publications (35)
Merck
→
Page 1 of 35
Results →
- March–April 2023
- Article
The New-Collar Workforce
By: Colleen Ammerman, Boris Groysberg and Ginni Rometty
Many workers today are stuck in low-paying jobs, unable to advance simply because they don’t have a bachelor’s degree. At the same time, many companies are desperate for workers and not meeting the diversity goals that could help them perform better while also reducing... View Details
- October 2020
- Teaching Plan
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details
- September 2020
- Case
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details
- December 2018
- Case
Corporate Transformation at Merck KGaA, Darmstadt, Germany
By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
- January 2018
- Case
Merck CEO Ken Frazier Quits President Trump's Advisory Council
By: Andy Zelleke and Brian Tilley
In the first six months of Donald Trump’s presidency, Merck CEO Kenneth Frazier appeared alongside Trump at least three times at press events, one of which commemorated the first and only meeting of the president’s Manufacturing Job Initiative (better known at the... View Details
- January 2017
- Case
Bayer AG: Bidding to Win Merck's OTC Business
By: Benjamin C. Esty, Marc Baaij and Arjen Mulder
Shortly after submitting their best and final offer to acquire Merck's Consumer Care Division (a collection of "over-the-counter" (OTC) products with sales totaling $2 billion), the Bayer M&A team was given a chance to revise their bid because another potential... View Details
- August 2013
- Teaching Plan
Remicade-Simponi
By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
- April 2012 (Revised May 2012)
- Case
Merck: Operating Science-Based Business
By: Ananth Raman, Inga Maurer and William Schmidt
Merck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure? View Details
- May 2011 (Revised July 2012)
- Exercise
Remicade/Simponi: Confidential Instructions for Johnson & Johnson
By: Guhan Subramanian and Rhea Ghosh
This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details
- May 2011 (Revised July 2012)
- Exercise
Remicade/Simponi: Confidential Instructions for Merck
By: Guhan Subramanian and Rhea Ghosh
This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details
- September 2010
- Case
Merck: Investing in Science-Based Business (Abridged)
By: Ananth Raman and Inga Katharina Maurer
Ray Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless... View Details
- April 2009
- Case
Merck: Managing Vioxx (A)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient... View Details
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
- October 2006
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)
By: Lynn S. Paine
- November 2004
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B)
By: Lynn S. Paine
Teaching Note to (9-398-033) and (9-398-034). View Details
- May 2004 (Revised June 2004)
- Case
Brief Biographical Note on P. Roy Vagelos
By: Nitin Nohria and Bridget Gurtler
Provides background biographical information on P. Roy Vagelos, chief executive officer of Merck Pharmaceuticals. Teaching Purpose: To chart the development of a leader in the pharmaceutical industry. View Details
- June 2003
- Teaching Note
Discovering the Future: R&D Strategy at Merck (TN)
By: Gary P. Pisano
Teaching Note for (9-601-086). View Details
Keywords: Pharmaceutical Industry
- April 2002
- Supplement
Grey Warner, Merck Latin America
By: Michael Beer
Grey Warner, the vice president of Merck's Latin America region, discusses the challenges raised in the case and the lessons learned. View Details
- September 2001 (Revised October 2001)
- Teaching Note
Merck & Company: Evaluating A Drug Licensing Opportunity TN
By: Richard S. Ruback and Aldo Sesia
Teaching Note for (9-201-023). View Details
Keywords: Service Industry